Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins
The discovery of mutated oncogenes has opened up a new era for the development of more
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Y Wang, G Schmid-Bindert… - Therapeutic advances in …, 2012 - journals.sagepub.com
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
JJ Yang, HJ Chen, HH Yan, XC Zhang, Q Zhou, J Su… - Lung cancer, 2013 - Elsevier
BACKGROUND: There is no published overview of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer …
tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer …
Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: comparison between t790m …
A Hata, N Katakami, H Yoshioka, J Takeshita… - Cancer, 2013 - Wiley Online Library
BACKGROUND The secondary epidermal growth factor receptor (EGFR) mutation
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
C Rolfo, E Giovannetti, DS Hong, T Bivona… - Cancer treatment …, 2014 - Elsevier
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations
I Garcia-Olivé, E Monsó, F Andreo… - European …, 2010 - Eur Respiratory Soc
The presence of somatic mutations of the tyrosine kinase domain of the epidermal growth
factor receptor (EGFR) gene in patients with advanced nonsmall cell lung cancer (NSCLC) …
factor receptor (EGFR) gene in patients with advanced nonsmall cell lung cancer (NSCLC) …
Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring
DH Josephs, DS Fisher, J Spicer… - Therapeutic drug …, 2013 - journals.lww.com
The treatment of many malignancies has been improved in recent years by the introduction
of molecular targeted therapies. These drugs interact preferentially with specific targets that …
of molecular targeted therapies. These drugs interact preferentially with specific targets that …
[HTML][HTML] The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
WZ Zhong, Q Zhou, YL Wu - Oncotarget, 2017 - ncbi.nlm.nih.gov
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have been
established as the standard therapy for EGFR-sensitizing mutant advanced non-small-cell …
established as the standard therapy for EGFR-sensitizing mutant advanced non-small-cell …
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
J Cadranel, AM Ruppert, M Beau-Faller… - Critical reviews in …, 2013 - Elsevier
Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …